产品说明书

Efavirenz

Print
Chemical Structure| 154598-52-4 同义名 : 依非韦伦 ;DMP 266;EFV;United Drug brand of efavirenz;Merck Sharp and Dohme brand of efavirenz;Stocrin;Sustiva;L-743726
CAS号 : 154598-52-4
货号 : A909233
分子式 : C14H9ClF3NO2
纯度 : 98%
分子量 : 315.675
MDL号 : MFCD05662344
存储条件：

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 40 mg/mL(126.71 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Efavirenz is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture[3]. Efavirenz is a non-nucleoside analog reverse transcriptase inhibitor (NNRTI) with IC50 of 60 nM[4]. Efavirenz inhibits synthesis using an RNA PPT-primed substrate with an IC50 of 17 nM[5]. Efavirenz is administered once-daily and its simple dosing schedule improves adherence to therapy allowing for durability of the virologic and clinical responses[6]. Efavirenz exerts a lysergide (LSD)-like effect on brain serotonergic pathways and affects CNS metabolic pathways, including mitochondrial function[7].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01837277 Severely Immunocompromised HIV... 展开 >> Patients 收起 << Phase 2 Phase 3 Unknown March 2016 Brazil ... 展开 >> Fundação Bahiana de Infectologia/SEI Not yet recruiting Salvador, Bahia, Brazil, 40010-160 Contact: Estela Luz, RN, MSci    32838123    eluz5@yahoo.com.br    Principal Investigator: Carlos Brites, MD, PhD          Sub-Investigator: Fabianna Bahia, MD, PhD          Universidade Federal do Rio de Janeiro Not yet recruiting Rio de Janeiro, RJ, Brazil Contact: Monica Ponze, RN    5521222739073       Principal Investigator: Mauro Schechter, MD, PhD          Hospital de Clinicas de Porto Alegre Not yet recruiting Porto Alegre, RS, Brazil Contact: Priscila Pelaez, MD          Principal Investigator: Eduardo Sprinz, MD, PhD 收起 <<
NCT00002227 HIV Infections Phase 2 Completed - United States, District of Col... 展开 >>umbia Richard Elion Washington, District of Columbia, United States, 20009 The Whitman Walker Clinic Washington, District of Columbia, United States, 20009 United States, Massachusetts Community Research Initiative of New England Brookline, Massachusetts, United States, 02445 United States, Ohio Remington Davis Inc Columbus, Ohio, United States, 43215 United States, Pennsylvania The Milton S Hersey Med Ctr / Div of Hematology Hershey, Pennsylvania, United States, 170330850 United States, South Carolina Coastal Carolina Research Ctr Mount Pleasant, South Carolina, United States, 29464 United States, Texas Montrose Clinic Houston, Texas, United States, 77006 United States, Virginia Hampton Roads Med Specialists Hampton, Virginia, United States, 23666 收起 <<
NCT00002225 HIV Infections Phase 2 Completed - United States, District of Col... 展开 >>umbia The Whitman Walker Clinic Washington, District of Columbia, United States, 20009 United States, Illinois AIDS Research Alliance - Chicago Chicago, Illinois, United States, 60657 United States, New York North Shore AIDS Hosp / Division of Infectious Disease Manhassett, New York, United States, 11030 Univ of Rochester Med Ctr Rochester, New York, United States, 14642 United States, North Carolina Carolinas Research Associates Charlotte, North Carolina, United States, 28207 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.17mL

0.63mL

0.32mL

15.84mL

3.17mL

1.58mL

31.68mL

6.34mL

3.17mL
参考文献

[1]Held DM, Kissel JD, et al. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem. 2006 Sep 1;281(35):25712-22.

[2]Young SD, Britcher SF, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1995 Dec;39(12):2602-5.

[3]Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1995 Dec;39(12):2602-5

[4]Held DM, Kissel JD, Saran D, Michalowski D, Burke DH. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem. 2006 Sep 1;281(35):25712-22

[5]Grobler JA, Dornadula G, Rice MR, Simcoe AL, Hazuda DJ, Miller MD. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem. 2007 Mar 16;282(11):8005-10

[6]Maggiolo F. Efavirenz. Expert Opin Pharmacother. 2007 Jun;8(8):1137-45

[7]Van de Wijer L, Schellekens AFA, Burger DM, Homberg JR, de Mast Q, van der Ven AJAM. Rethinking the risk-benefit ratio of efavirenz in HIV-infected children. Lancet Infect Dis. 2016 May;16(5):e76-e81